



OPEN

## c-di-AMP signaling plays important role in determining antibiotic tolerance phenotypes of *Mycobacterium smegmatis*

Aditya Kumar Pal & Anirban Ghosh

In this study, we probe the role of secondary messenger c-di-AMP in drug tolerance, which includes both persister and resistant mutant characterization of *Mycobacterium smegmatis*. Specifically, with the use of c-di-AMP null and overproducing mutants, we showed how c-di-AMP plays a significant role in resistance mutagenesis against antibiotics with different mechanisms of action. We elucidated the specific molecular mechanism linking the elevated intracellular c-di-AMP level and high mutant generation and highlighted the significance of non-homology-based DNA repair. Further investigation enabled us to identify the unique mutational landscape of target and non-target mutation categories linked to intracellular c-di-AMP levels. Overall fitness cost of unique target mutations was estimated in different strain backgrounds, and then we showed the critical role of c-di-AMP in driving epistatic interactions between resistance genes, resulting in the evolution of multi-drug tolerance. Finally, we identified the role of c-di-AMP in persister cells regrowth and mutant enrichment upon cessation of antibiotic treatment.

Bacterial second messengers are a group of nucleotide-derived small molecules that modulate important cellular pathways in different bacteria. A few examples of those messenger molecules are (p)ppGpp, c-di-GMP, c-di-AMP, cGAMP etc.<sup>1–6</sup>. So far, especially in Gram-positive organisms, c-di-AMP has been shown to contribute to different biological processes such as DNA repair, K<sup>+</sup> transport, osmotic balance maintenance, cell wall metabolism, virulence etc.<sup>7–11</sup>. In some cases, it was also studied to induce the type I interferon response in mammalian cells<sup>12,13</sup>. Our group was specifically interested to study if c-di-AMP could play an important role in terms of promoting antibiotic tolerance in mycobacteria. Though there are few studies of c-di-AMP in *M. smegmatis* and *M. tuberculosis*<sup>14–19</sup> which mainly highlighted key pathways regulated by c-di-AMP, there was no study that exclusively described the physiological role of this important small molecule to promote resistant mutant generation in any bacteria. Since one of the recent studies identified a potential impact of varying intracellular c-di-AMP concentration regulating distinctive drug susceptibility phenotypes in *M. smegmatis*<sup>20</sup>, we wanted to continue a further investigation in the same direction to understand such differential drug tolerance mechanisms and increased probability of resistant mutant generation. In *Mycobacterium smegmatis*, c-di-AMP is constitutively synthesized from the condensation of two ATP molecules by enzyme DisA and hydrolyzed by enzyme Pde into pApA<sup>14</sup>; often this steady-state homeostasis gets unbalanced as a part of stress adaptation. As a matter of course, a further understanding was demanded if and how the varying c-di-AMP concentration could play a role in the antibiotic resistance phenotype of the cells and our data indeed highlighted the strong correlation between intracellular c-di-AMP concentration and the evolution of resistant mutants. We elucidated the mechanistic insights and our model suggests the role of c-di-AMP concentration in determining specific categories of mutations in different growth phases. Next, we revealed the unexpected role of c-di-AMP in controlling epistatic interaction between two resistance genes of mycobacteria and thus stimulating multi-drug resistance phenotype. Finally, we show how c-di-AMP contributes to the resuscitation of persisters by transcriptional regulation of resuscitation-promoting factors through a putative riboswitch element. All in all, this study discusses the physiological relevance of c-di-AMP in modulating the antibiotic resistance profile of *M. smegmatis* and possible implications in the evolution of persisters and resistant mutants.

Molecular Biophysics Unit, Indian Institute of Science, Bangalore 560012, India. email: ganirban@iisc.ac.in

## Materials and methods

**Bacterial strains, media and growth conditions.** *Mycobacterium smegmatis* mc<sup>2</sup>155 (WT) and its knockout variants  $\Delta disA$  &  $\Delta pde$  and their respective complemented strains ( $\Delta disA + pDisA$ ) & ( $\Delta pde + pPde$ ) were grown in Middlebrook 7H9 broth (MB7H9; HiMedia) with 2% (wt/vol) glucose as a carbon source and 0.05% (vol/vol) tween-80, Agar (1.5%, w/v) (HiMedia) at 37 °C. The antibiotics kanamycin and hygromycin were used at a concentration of 25 µg/ml and 50 µg/ml respectively<sup>20</sup>. ciprofloxacin, rifampicin and Ofloxacin powder were obtained from Sigma-Aldrich, USA and Sisco Research Laboratories, India. Antibiotics were used at variable concentrations.

**Estimation of resistant mutation frequencies and rates.** As previously described by Kurthkoti et al.<sup>21</sup>, single colonies from *M. smegmatis* strains were grown in Middlebrook 7H9 medium to an optical density (OD at 600 nm, OD<sub>600</sub>) of 1.2–1.5. Next, 1% of the inoculum had given to a fresh 10 ml of media and kept at 37 °C shaking. 1 ml of cultures of each strain was taken from exponential (OD<sub>600</sub> 0.7–0.8) and stationary (OD<sub>600</sub> 2.5–3) phase cultures and concentrated by 5 times. 100 µl of the culture was plated in triplicate on MB agar plates containing antibiotics to get the mutant cell count and the remaining cultures were diluted till 10<sup>-7</sup> dilution and 100 µl of selective dilutions were plated in triplicate onto an antibiotic-free MB agar for CFU determination (drug-free control). Mutation frequencies were calculated by dividing the number of colonies on a drug-containing plate by the number of colonies on the drug-free plate as described by Swaminath et al.<sup>22</sup>. In addition, 50–100 colonies were chosen randomly from the drug-containing plates for further characterization.

Spontaneous mutation rates of *M. smegmatis* strains to ciprofloxacin and rifampicin were determined by the Luria-Delbrück fluctuation analysis using the method described by David et al.<sup>23</sup> with minor modification. Single colonies of *M. smegmatis* wild-type,  $\Delta disA$  and  $\Delta pde$  strains were grown in Middlebrook 7H9 medium to OD<sub>600</sub> of 1.2–1.5 and for each strain, 1000–1500 cells/ml of inoculum were transferred into 10 tubes and kept at 37 °C shaking for 6 days. For selecting the spontaneous mutants, the whole culture was concentrated by 3 times and plated on a drug-containing plate and 50 µl was kept aside for the CFU estimation. Mutation rates were calculated by the Luria and Delbrück formula described by Luria et al.<sup>24</sup> (Fig. S1d).

**Ultra-violet stress induced mutation frequency.** *M. smegmatis* strains were grown until the mid-log phase and then normalized to OD<sub>600</sub> 0.7. 1 ml of this culture was exposed to UV irradiation (0.125 mJ/cm<sup>2</sup>)<sup>25</sup>. After that, the aliquots from the UV treated and untreated cultures were diluted into fresh Middlebrook 7H9 broth to an OD<sub>600</sub> of 0.03 and kept at 37 °C shaking for 5 days. On the fifth day, the 100 µl of the cultures were spread onto rifampicin plates (10X MIC: minimum inhibitory concentration) to estimate the resistant mutant population and also 50 µl of culture was taken for the CFU estimation in an antibiotic-free plate. Mutation frequency was determined using the formula discussed in the mutation frequency method section.

**Plasmid based NHEJ in-vivo assay.** The non-homologous end-joining (NHEJ) reporter plasmid pMV261-*lacZ* (hygromycin marker) was constructed by cloning a functional copy of the *lacZ* gene from the pSD5B vector using the HindIII restriction site in specific primers (Table S7). For in vivo NHEJ reporter assay, we adapted the protocol from a previously published paper by Gong et al.<sup>26</sup>. In our case, the pMV261-*lacZ* reporter vector was digested with blunt cutter restriction enzyme SspI. The linear plasmid was purified by agarose gel electrophoresis and the DNA concentration was quantified by UV absorbance. The same concentration of linear and circular DNAs (uncut pMV261-*lacZ* plasmid) was transformed into different *M. smegmatis* strains by electroporation and plated on Middlebrook agar containing hygromycin (50 µg/ml) and X-gal (40 µg/ml). Transformations were done in triplicates for each strain and the plates were kept at 37 °C for 72 h. Colonies were counted after 72 h. The blue colony colour indicated an intact *lacZ* coding sequence; whereas the white colonies indicated that the *lacZ* gene was inactivated during the repair process. NHEJ efficiency was calculated by the ratio of CFU per nanogram of transformed linear DNA and circular DNA. NHEJ fidelity was calculated as the percentage of blue colonies out of the total number of colonies<sup>26</sup>. A few white mutant colonies of  $\Delta pde$  pMV261-*lacZ* were isolated from the plate and streaked onto a new X-gal containing plate to reconfirm the loss of *lacZ* function. Colony PCR was performed by taking one single colony dissolved in 50 µl of autoclaved water. PCR products were isolated by using the Qiaquick PCR cleanup kit (Qiagen) and then sequenced directly using the *lacZ*\_MIDREV2 primer (Table S7) to detect mutations.

**Minimum Inhibition Concentration (REMA) assay.** MIC values were estimated using REMA (Resazurin microtiter assay) adapted from an earlier protocol<sup>27</sup>. In brief, the transmittance of the culture was adjusted to a McFarland turbidity standard of 1 and then diluted to 1:10. Next, 196 µl portions of the diluted culture were inoculated into 96 well microtiter plates containing a twofold serial dilution of the antibiotics (4 µl). Plates were sealed and incubated at 37 °C for 36 h. Next, 30 µl of 0.01% resazurin dye was added to each well, and the plates were further incubated for 4–6 h. The color of the resazurin changed from blue to pink due to bacterial growth. The MIC was determined as the minimum antibiotic concentration at which the resazurin dye did not change the color.

**Mutation mapping of cip<sup>R</sup> and rif<sup>R</sup> mutants.** Antibiotic-resistant mutant colonies were isolated from different concentrations of drug-containing plates, inoculated into the same antibiotic containing Middlebrook 7H9 complete media and were grown in shaking at 37 °C, till the mid-log phase (MLP). The genomic DNA of the mutants was isolated using the phenol–chloroform extraction method<sup>28</sup> after the overnight lysis procedure. The quinolone resistance determining region (QRDR) of *gyrA* and the rifampicin resistance determining region

(RRDR) of the *rpoB* gene, which are considered to be the hotspots for acquiring mutations of the respective genes were amplified from the genomic DNA of respective resistant mutants using the specific primer pairs (Table S7). The sequencing reactions were performed by Medauxin, India.

**EtBr efflux Assay.** Efflux assay was adapted from a previous publication<sup>29</sup> by Li et al. Briefly, *M. smegmatis* cultures were grown at 37 °C in MB7H9 medium to an optical density at 600 nm of 0.9–1. Cells were then washed twice with phosphate buffer saline with 0.05% tween80, resuspended in 1/3<sup>rd</sup> volume of the same buffer kept at 37 °C shaking for one hour for starvation. After that, 100 µM of the efflux pump inhibitor CCCP (carbonyl cyanide m-chlorophenylhydrazone)<sup>30</sup> were added and the cells were further incubated for 30 min in the same condition. Next, Ethidium bromide (0.5 µg/ml final concentration) was added and cells were incubated for another 30 min. After that, cells were washed with the 1XPBST in the same volume to remove the CCCP and extracellular EtBr. After that, cells were taken into 96 well black plates and 2% glucose was added to the wells to facilitate efflux activity. To quantify the efflux of EtBr fluorescence was checked for the next one hour (with a 1-min interval between two readings) in the Varioskan Flash multimode reader (Thermo Fisher Scientific) at 530 nm and 590 nm wavelengths for excitation and emission respectively.


**Fitness cost estimation of mutants and analysis of epistatic interaction.** Ciprofloxacin resistant (*cip*<sup>R</sup>) mutants were grown in MB7H9 media till the mid-exponential phase, washed and inoculated into M9 minimal media containing 1 mM MgCl<sub>2</sub>, 0.3 mM CaCl<sub>2</sub> with 0.2% glucose<sup>31</sup> by adjusting the final OD<sub>600</sub> 0.03. 5 ml of such cultures were taken in a sterile glass tube and kept at 37 °C shaking for 120 h and OD<sub>600</sub> was measured in equal intervals. To check if the fitness cost of certain *cip*<sup>R</sup> mutants was reversed by a secondary mutation and emergence of rifampicin resistance, cells were plated on rifampicin (10X MIC) plates after 120 h of growth in M9 minimal media, and the mutation rate was calculated.

**Regrowth and resuscitation assay with mutant enrichment determination.** *M. smegmatis* Cultures were grown till the late exponential or early stationary phase (OD<sub>600</sub> of 1.5–2.5), diluted in 1:100 to start a secondary culture, and grown till the mid-exponential phase (OD<sub>600</sub> of 0.6–1) and further diluted to adjust to OD<sub>600</sub> of 0.2 corresponding to ~2 X10<sup>7</sup> CFU/ml (CFU = colony-forming unit) in fresh MB7H9 medium. 5 ml of such culture was taken for ciprofloxacin (3X MIC) treatment at 37 °C shakers. CFU estimations (plating) were done every 12 h for up to 72 h. In parallel to the CFU estimation, spotting and spreading was done on ciprofloxacin (1.25 µg/ml) plates to enumerate resistant mutant population enrichment over time. In the case of resuscitation assay (10X ciprofloxacin), after 24 h of treatment, cultures were washed to remove antibiotics and resuspended in fresh MB7H9 media without antibiotics followed by incubation at 37 °C shaker and CFU estimations (plating) were done every 24 h of up to 96 h. Plates were further incubated at 37 °C for 3–4 days for colony growth and subsequently counted.

**GFP expression measurement of the promoter fusion construct.** The *rpfa* gene reporter constructs were made in promoter-less GFP vector pMN406-*Δimy*<sup>32</sup> (a generous gift from Prof. Ajitkumar, Indian Institute of Science, India). To generate transcriptional fusions, a 434 bp fragment from the upstream region of the gene *MSMEG\_5700* was PCR amplified from *M. smegmatis* mc<sup>2</sup>155 gDNA using a compatible set of primers, as mentioned in (Table S7). The PCR fragment was then subsequently cloned into the reporter vector upstream of GFP using restriction enzymes and transformed into Wild-type, *ΔdisA* and *Δpde* strains and the transformants were selected against hygromycin. To measure the GFP induction during the resuscitation phase in different strains, 200 µl of the cells were taken in a black, flat bottom 96 well plate (Thermo Nunc) and GFP intensity was recorded at excitation of 488 nm and emission of 510 nm<sup>33</sup> in Varioskan Flash multimode reader (Thermo Fisher Scientific). GFP expression (RFU: relative fluorescence unit) was calculated by dividing GFP fluorescence intensity by cell density (OD 600 nm).

## Results

**High c-di-AMP concentration promotes the generation of spontaneous resistant mutants.** We designed our assay to evaluate if the fluctuating intracellular c-di-AMP concentration in *M. smegmatis* could have an impact on the resistant mutant generation against standard drugs. First, we started with two deletion mutants constructed in our group *M. smegmatis* *ΔdisA* and *M. smegmatis* *Δpde*, which correspond to c-di-AMP null mutant and over-expressing mutant strains respectively (manuscript under review<sup>20</sup>). *M. smegmatis* WT, *ΔdisA* and *Δpde* strains along with their respective complementation strains were harvested in different growth phases to isolate resistant mutants. *M. smegmatis* cells were grown till the early stationary phase and spread on high concentration (10X MIC) of ciprofloxacin plates and the number of resistant mutants was counted (Fig. S1a). It was found that the in vitro, spontaneous mutants of *M. smegmatis* *Δpde* resistant to ciprofloxacin arose at frequencies of 7.9 × 10<sup>-7</sup> whereas for *M. smegmatis* WT strain's resistance frequency remained low ~4.5 × 10<sup>-8</sup>. This ~18-fold increase in resistance frequency was directly correlated to high c-di-AMP concentration as the complementation strain *M. smegmatis* *Δpde* + pMV361-*pde* had a similar resistance frequency to WT ~5.2 × 10<sup>-8</sup> (Fig. 1A). For *M. smegmatis* *ΔdisA* strain there was no significant increase in resistance frequency (8.3 × 10<sup>-8</sup>) and similar values were observed with complementation strain *M. smegmatis* *ΔdisA* + pMV361-*disA* (Fig. 1A). Next, we wanted to check if this c-di-AMP driven resistance phenotype is specific for well-grown stationary phase cultures only or not, and thus repeated the assay with exponentially grown cultures of the same strains (Fig. S1a) and we found that the *M. smegmatis* *Δpde* strain had a ~5-fold high resistance frequency compared to WT, whereas *M. smegmatis* *ΔdisA* strain had a similar resistance profile like WT (Fig. S1b). As expected, both complementation strains behaved like WT further corroborating the relevance of high c-di-AMP concentration



**Figure 1.** Modulating intracellular c-di-AMP concentration affects the number of spontaneous resistant mutants against ciprofloxacin and rifampicin. (A) ciprofloxacin mutation frequency and (B) rifampicin mutation frequency were calculated for *M. smegmatis* WT, *M. smegmatis*  $\Delta disA$ , *M. smegmatis*  $\Delta pde$  and their respective complementation strains [N=3]. All the strains were grown till stationary phase. Similarly, (C) ciprofloxacin mutation rate and (D) rifampicin mutation rate were calculated for *M. smegmatis* WT, *M. smegmatis*  $\Delta disA$ , *M. smegmatis*  $\Delta pde$  along with respective complementation strains [N=3]. All the graphs are plotted using GraphPad Prism8, unpaired t-test was used to calculate statistical significance: \*\*\*\*P < 0.001; \*\*P < 0.01; \*P < 0.05; ns = non-significant.


with higher mutation frequency across all growth phases. In general, all the strains grown to the stationary phase showed higher mutation frequency compared to the respective exponentially grown cultures under an identical assay setup. To find out, if the hypermutant phenotype of *M. smegmatis*  $\Delta pde$  strain was not specific to the DNA damaging antibiotic ciprofloxacin, we checked the resistance frequency of the strains against RNA polymerase inhibitor rifampicin and we noted a significant ~44-fold increase in resistance frequency for the  $\Delta pde$  strain. Surprisingly, the  $\Delta disA$  strain also showed a ~29-fold increase in resistance frequency compared to WT, unlike ciprofloxacin. As expected, both the complementation strains had similar MF (resistance frequency) values to WT (Fig. 1B, Fig. S1c).

Spontaneous mutation rates were estimated (Fig. S1d) against ciprofloxacin and rifampicin for all 5 strains and a similar observation in terms of increase in mutation rate was observed in the  $\Delta pde$  strain, which further confirmed the direct role of c-di-AMP in promoting antibiotic resistance (Fig. 1C). As a similar observation with the mutation frequency assay with rifampicin, *M. smegmatis*  $\Delta disA$  showed a significant increase in mutation rate (Fig. 1D). The specific fold change in spontaneous mutation rates of the strains was illustrated in Table 1. At this point, we speculated whether the selective increase in the probability of spontaneous rifampicin mutation of  $\Delta disA$  strain was due to the lack of the DisA scanning enzyme or c-di-AMP messenger. Hence, we repeated the assay  $\Delta disA$  strain with complementation of a *disA* mutant (D84A), incapable of synthesizing c-di-AMP<sup>34</sup> but unaffected in DNA binding. Our data indicated a significant drop in the mutation rate of the  $\Delta disA$  strain when complemented with pMV361-*disA*(D84A) plasmid, similar to pMV361-*disA*(WT) plasmid complementation (Fig. S1e). This observation led us to believe that, possibly due to the lack of DisA enzyme's DNA scanning properties (and not because of the inability to synthesize c-di-AMP), the  $\Delta disA$  strain showed a significant increase in the mutation rate against rifampicin.

**The high c-di-AMP strain becomes more prone to UV-induced mutation.** After confirming a significant increase in spontaneous mutation rate in the  $\Delta pde$  strain, we wanted to estimate the effect of induced mutation with a known mutagenic agent: UV irradiation. Here, we exposed the *M. smegmatis* cells to UV

Strains	Ciprofloxacin		Rifampicin	
	Mutation rate ( $\times 10^{-7}$ )	Fold increase	Mutation rate ( $\times 10^{-7}$ )	Fold increase
WT	0.002 $\pm$ 0.000	1	0.016 $\pm$ 0.001	1
$\Delta disA$	0.051 $\pm$ 0.005	<b>25.5</b>	0.633 $\pm$ 0.033	<b>39.56</b>
$\Delta pde$	0.802 $\pm$ 0.033	<b>401</b>	0.517 $\pm$ 0.019	<b>32.3</b>
$\Delta disA + pDisA$	0.004 $\pm$ 0.000	2	0.009 $\pm$ 0.001	0.56
$\Delta pde + pPde$	0.004 $\pm$ 0.000	2	0.005 $\pm$ 0.002	0.13


**Table 1.** Specific fold changes in spontaneous mutation rates for different strains against ciprofloxacin and rifampicin. Significant values are in [bold].



**Figure 2.** (A) A bigger fold change in rifampicin mutation rate was observed for *M. smegmatis*  $\Delta pde$  strain compared to *M. smegmatis* WT strain after UV induced mutagenesis [N = 3]. (B) Representative microscopic images were shown to compare cell damage, cell filamentation and chromosome disintegration in both *M. smegmatis* WT and *M. smegmatis*  $\Delta pde$  strain after a sublethal dose of UV exposure (0.125 mJ/cm<sup>2</sup>). A lack of cellular filamentation in  $\Delta pde$  strain was indicative of the absence of RecA-mediated SOS repair in  $\Delta pde$  strain; white arrows indicate severe DNA condensation and damage. Microscopy scale bars = 2  $\mu$ m. A plasmid-based assay was performed to estimate the NHEJ-driven repair phenomenon. Though (C) NHEJ efficiency was comparable between *M. smegmatis* WT and  $\Delta pde$  strain [N = 3], a significant drop in (D) NHEJ repair fidelity (~19%) was observed due to error-prone *lacZ* reannealing [N = 3]. (E) Knockdown of the principal NHEJ component Ku [by antisense (AS) approach] reversed the hypermutation phenotype in *M. smegmatis*  $\Delta pde$  strain, estimated by resistance frequency calculation against ciprofloxacin [N = 3]. All the graphs are plotted using GraphPad Prism8 (N = 3), unpaired t-test was used to calculate statistical significance: \*\*\*\*P < 0.001; \*\*P < 0.01; \*P < 0.05; ns = non-significant.

(0.12 mJ/cm<sup>2</sup>); this particular dose was optimized to ensure minimum cell death while demonstrating the maximum mutagenic capacity. Post UV exposure, cells were allowed to recover and were spread on an antibiotic-containing plate to estimate the extent of genome-wide mutations due to UV induced double-strand break and inaccurate repair. In this study, we have included rifampicin (10X MIC) as a selection platform to isolate *rpoB* mutants and as a control, we grew the non-UV exposed cells for 5 days and plated them on the same rifampicin concentration plate to compare the increase in mutation rate specifically after UV exposure. As expected, and as a part of the validation of our assay, we found irrespective of the strain background, *M. smegmatis* WT,  $\Delta disA$ , and  $\Delta pde$  all showed a significant increase in mutation rate upon UV exposure (~40–120 fold) compared to their respective untreated controls under identical assay setup. Comparison in the fold increase of mutation rate showed the highest for the  $\Delta pde$ , i.e., 109-fold; which was significantly higher than WT which showed about a 78-fold increase (Fig. 2A). The higher fold increase of mutation rate in high c-di-AMP strain reconfirmed our previous observation linking increased c-di-AMP level with enhanced hypermutation phenotype. Microscopic observation of the cells after UV exposure revealed more prominent cell damage and chromosome condensation





**Figure 3.** (A) Increased c-di-AMP concentration determines the mutational landscape and results in the high probability of non-QRDR (Category-I) mutations in  $\Delta pde$  strain, which are only resistant at to 10X MIC, but do not survive at higher 60X MIC of ciprofloxacin. A two-way ANOVA test was performed to check statistical significance [N = 3]. (B) EtBr efflux assay demonstrated a high degree of efflux activity in category I  $cip^R$  (non-QRDR) mutant, but not in category II  $cip^R$  (with a QRDR SNP) mutant or parental strains [N = 3]. (C) High fitness cost associated with D94N mutation in the GyrA protein subunit was observed in the case of  $\Delta pde$  ( $cip^R$  category II mutant) when cells had growth deficiency in minimal media and the fitness cost was neutralized to the *M. smegmatis*  $\Delta pde$  parental strain level by acquiring a second compensatory mutation ( $rif^R$ ) after prolonged growth in M9 minimal media for 5 days [N = 3]. Estimation of the specific role of high intracellular c-di-AMP concentration driving positive epistatic interactions: (D) increased rifampicin mutation frequency of a  $cip^R$  category II mutant to become double mutant ( $cip^R$ ,  $rif^R$ ) was only favored when intracellular c-di-AMP concentration was high (in  $\Delta pde$  background), but not in WT background [N = 3] and (E) rifampicin mutation frequency dropped in  $\Delta pde$   $cip^R$  category II mutant when normal physiological level of c-di-AMP was restored with pMV361-*pde* complementation [N = 3]. All the graphs are plotted using GraphPad Prism8, unpaired t-test was used to calculate statistical significance: \*\*\*P < 0.001; \*\*P < 0.01; \*P < 0.05; ns = non-significant.


in the  $\Delta pde$  strain (Fig. 2B). The lack of cellular filamentation in the  $\Delta pde$  strain was also possibly an indication of the absence of RecA-mediated SOS repair. Finally, sequencing of the RRDR region of the *rpoB* gene in rifampicin-resistant ( $rif^R$ ) clones revealed a histidine to tyrosine substitution in the 442<sup>nd</sup> amino acids, further confirming the molecular basis of rifampicin resistance (data not shown).

**The in vivo NHEJ assay revealed a high degree of error-prone repair in  $\Delta pde$  strain.** Next, we wanted to understand the underlying molecular mechanism of the enhanced mutation phenotype of the  $\Delta pde$  strain. As it has been already highlighted how the RecA enzyme's function is severely compromised in presence of excess c-di-AMP in the system<sup>15</sup>, we hypothesized that DNA repair function in such cases becomes largely dependent on the non-homologous end joining (NHEJ) pathway, which is usually considered to be a last-resort, error-prone repair mechanism<sup>35</sup>. To prove our hypothesis, we adopted a plasmid-based assay to estimate NHEJ-driven repair and compared the accuracy of repair between WT and  $\Delta pde$  strain (Fig. S2a). We used the pMV261-*lacZ* reporter plasmid where a functional *lacZ* gene was linearized (single cut) with blunt cutter restriction enzyme SspI, then the DNA was electroporated into cells with varying c-di-AMP concentrations and selected on a hygromycin + X-gal plate. This ensured simultaneous screening for both antibiotic resistance acquisition (which was possible due to reannealing at the SspI cut site) and *lacZ* enzyme function (which was only possible if the repair is error-free). The total number of blue colonies was counted to determine successful repair events of *lacZ* and the ratio of blue and white colonies estimated the overall repair fidelity of the reporter plasmid. As expected, the uncut reporter plasmid served as a parallel control where all the transformed cells appeared as blue colonies resulting in 100% fidelity. After we made sure the transformation efficiency and NHEJ efficiency is comparable between WT and  $\Delta pde$  strains (Fig. 2C), we calculated the percentage of blue colonies on the hygromycin + Xgal plate to estimate faithful repair events. Our data suggested that there is a significant drop in the *lacZ* repair fidelity (~19%) in the  $\Delta pde$  strain due to error-prone NHEJ repair events (Fig. 2D). Further analysis of repair sites by sequencing revealed the appearance of different base insertions and deletions (Table S1) at the SspI restriction site resulting in a frameshift of the amino acid reading frame, which typically occurred due to NHEJ repair, thus reconfirming our hypothesis about the high probability NHEJ driven error-prone repair in high c-di-AMP strain.

**Knockdown of NHEJ component Ku reversed the hypermutation phenotype of  $\Delta pde$  strain.** As our plasmid-based repair assay revealed a definite role of the NHEJ mechanism in generating resistant mutants, we wanted to check if the inactivation of Ku protein (the principal component of the NHEJ repair pathway)<sup>36</sup> could make any difference in  $\Delta pde$  strain's mutational outcome. For this, we adopted the antisense strategy to conditionally knock down the *ku* gene (*MSMEG\_5580*) in  $\Delta pde$  strain by overexpressing *ku* gene in the reverse orientation (antisense, AS) from the pMV261 vector (pMV261 *ku*-AS). Upon checking MIC (Table S2) and repeating the mutation frequency determination assay at 10X MIC of ciprofloxacin, we found, as expected, that the  $\Delta pde$  strain showed a significant increase in resistance frequency compared to WT; but the *M. smegmatis*  $\Delta pde$  + pMV261-*ku*-AS strain showed no increase in the number of resistant mutants compared to WT counterpart of *M. smegmatis* + pMV261-*ku* AS (Fig. 2E). Hence, it was proved that the underlying mechanism of the hypermutation phenotype of the  $\Delta pde$  strain is directly linked to the error-prone NHEJ repair pathway. To check whether the hypermutation phenotype in  $\Delta pde$  strain could also be related to the elevated levels of free radicals<sup>37</sup>, we performed the resistance mutagenesis frequency experiment with thiourea (a known quencher of free radicals) treated cells (100 mM final concentration, pretreatment of cells before spreading onto ciprofloxacin plate). We could not observe any differences in terms of resistance frequency in thiourea-treated  $\Delta pde$  cells compared to untreated  $\Delta pde$  cells and in both cases, it showed a significant increase in Resistance frequency (~30 to 50-fold) compared to the respective WT series of thiourea treated and untreated cells (Fig. S2b). This observation nullified the other possibility of the high level of free radicals being responsible for generating a high number of resistant mutants in the case of the  $\Delta pde$  strain.

**Increased c-di-AMP concentration results in the high probability of non-QRDR mutations in  $\Delta pde$  strain.** We were further interested to investigate if the predominance of NHEJ repair in  $\Delta pde$  strain resulted in a different mutational landscape or not. To check that, we screened approximately 100 *cip*<sup>R</sup> clones that arose in the mutation frequency determination experiment for both WT and  $\Delta pde$  strains by patching them on low (10X MIC, original concentration at which they were isolated) and high concentrations of ciprofloxacin (60X MIC) plates (Fig. S3a); further on, we described them as category I and category II mutants respectively. When estimated, we found that the majority (~94%) of *cip*<sup>R</sup> mutants in  $\Delta pde$  strain background were category I mutant (only resistant at to 10X MIC, but does not survive at higher 60X MIC concentration) and only a minority of them (~6%) were able to survive at 60X MIC of ciprofloxacin. A similar comparison in WT *cip*<sup>R</sup> did not reveal any striking predominance of category I mutants over category II mutants (~58% vs 42%) (Fig. 3A). To validate this unexpected observation, we confirmed the different degrees of ciprofloxacin resistance phenotype of mutants by checking ciprofloxacin minimum inhibitory concentration (MIC) and found the MIC values were increased only by 16-fold for WT category I mutant (MIC 8  $\mu$ g/ml) and 128-fold for WT category II mutant (MIC 64  $\mu$ g/ml) compared to the WT parental strain (MIC 0.5  $\mu$ g/ml) (Table S3). Category II mutants were further tested for cross-resistance against another fluoroquinolone antibiotic ofloxacin and found to have a 64-fold increase in MIC further confirming target gene mutation (data not shown). Next, we sequenced the QRDR region of the representative category II mutants and all of them were identified as having unique point mutations in the 94<sup>th</sup> amino acid (aspartic acid) of GyrA protein, but no such mutations were detected in any of the category I mutants. At this point, we hypothesized that the category I mutants which showed a lesser degree of MIC modulation and no mutation in the QRDR hotspot region of the *gyrA* gene could harbor mutations leading to high efflux activity. To prove that, we repeated the ciprofloxacin MIC assay with efflux pump inhibitor CCCP (Carbonyl cyanide *m*-chlorophenyl hydrazone) at a non-toxic concentration (4  $\mu$ g/ml) and indeed we found a considerable decrease in MIC value for WT category I mutant (from 8 to  $\leq$ 0.125  $\mu$ g/ml), but the shift in MIC in presence of CCCP was moderate (~4 to 8-fold) in WT parental strain (0.5  $\mu$ g/ml) (Table S3). This data further indicated the presence of a certain mutation in the efflux pump in category I mutants. Next, we did an efflux assay using EtBr and observed a high degree of efflux activity in WT category I mutant only, but not in WT category II or parental strains (Fig. 3B). Similar observations were recorded for  $\Delta disA$  and  $\Delta pde$  strains (category I and category II mutants) (Fig. S3b). Finally, we sequenced the *lfrR* gene which serves as a repressor of well-known LfrA efflux protein<sup>38</sup>, and identified unique insertions in all category I mutant strains (Table S4), which have caused an ORF frameshift and complete loss of its repressor activity and thus resulted in the constitutive expression of LfrA. As expected, for category II mutants, we were unable to map any frameshift mutation in the *lfrR* gene, further signifying the effect of target mutation related to the high degree of resistance against ciprofloxacin (Table S4). Though we confirmed unique SNPs in the QRDR region of category II *cip*<sup>R</sup> mutants with WT and  $\Delta disA$  background (4 independent clones for each), for  $\Delta pde$  category II mutants it was only detected once (out of 4 clones sent for sequencing). From this data, it could be hypothesized that the c-di-AMP directed error-prone NHEJ repair (which usually results in frameshift mutation) in  $\Delta pde$  strain categorically avoided putting mutations in an essential gene *gyrA* or such frameshift mutants with complete loss of GyrA function eventually not got selected in the end.

**Specific QRDR mutations come with a high fitness cost.** Next, we estimated the fitness cost of each QRDR mutation across different strain backgrounds by growing them in stringent conditions such as M9 minimal media, without any ciprofloxacin and checked if the growth profile became different due to the acquisition of mutations in either *gyrA* or *lfrR* genes. The *gyrA* 94<sup>th</sup> amino acid mutation seemed to have a moderate fitness cost in WT and  $\Delta disA$  category II mutants (data not shown), but this deficiency in growth seemed to be most prominent in the case of  $\Delta pde$  strain category II mutant when compared to the parental strain (Fig. 3C), whereas category I mutants of  $\Delta pde$  did not reveal any growth deficiency whatsoever. As we had several category II  $\Delta pde$  mutants without any QRDR mutation detected, we checked their growth profile in M9 minimal media as well



**Figure 4.** (A) Regrowth of persisters (after 10X ciprofloxacin treatment and subsequent washing of the drug) was significantly decelerated by high c-di-AMP concentration in  $\Delta pde$  strain, unlike WT and the complementation strain ( $\Delta pde + pMV361-pde$ ) [N=3]. (B) Slower resuscitation of  $\Delta pde$  surviving cells results from a rapid enrichment of genetic mutants, around 93% of mutant population enrichment happened in  $\Delta pde$  strain within 24 h of the killing, whereas in the case of WT strain ~52% of cells became ciprofloxacin mutants [N=3]. (C) Significantly slower induction of the  $P_{rpfa}$  (as a GFP readout) in  $\Delta pde$  background confirms the molecular basis of slower persisters regrowth [N=3], when the c-di-AMP level was normalized in the same strain by a *disA* gene frameshift mutation,  $P_{rpfa}$  induction was almost restored to the WT level. All the graphs are plotted using GraphPad Prism8, unpaired t-test was used to calculate statistical significance: \*\*\*\*P < 0.001; \*\*P < 0.01; \*P < 0.05; ns = non-significant.

and found that non-QRDR category II mutants had less fitness cost compared to the QRDR category II mutants, though they have the same ciprofloxacin MIC (data not shown).

**c-di-AMP promotes positive epistatic interaction between resistance genes and results in multi-drug resistance.** Since it was clear that QRDR mutation usually comes with a high fitness cost, we were further interested to know if a second compensatory mutation could nullify the growth deficiency of a category II mutant. Hence, we grew the parental strain and category II QRDR mutants of both *M. smegmatis* WT and  $\Delta pde$  strain for 5 days in M9 media (where they exhibited moderate to high growth deficiency) and screened for the emergence of resistant mutants by plating on a different antibiotic rifampicin (10X MIC) plate. We found that only  $\Delta pde$  category II mutants formed many colonies on the rifampicin plate and showed a 30-fold increase in mutation frequency compared to *M. smegmatis*  $\Delta pde$  parental strain (Fig. 3D). In the case of WT strain, we could not see such an unanticipated emergence of rifampicin mutants without any pre-exposure to rifampicin. Next, we tested whether due to the acquisition of the second mutation (rifampicin resistance) the fitness cost of the category II mutant was neutralized or not, we checked the growth profile of the double mutant ( $cip^R, rif^R$ ) in M9 minimal media. Indeed, we found the strain has nullified the growth deficiency (Fig. 3C) with a second mutation ectopically linked with rifampicin resistance while retaining the first mutation ( $cip^R$ ) intact. Subsequently, we checked the rifampicin MIC of the double mutant, we found it was increased by only 16-fold to 32  $\mu\text{g/ml}$ , which is much lesser than the one-step isolated  $rif^R$  mutant of  $\Delta pde$  strain (512  $\mu\text{g/ml}$ ) (Table S5). As expected, *rpoB* gene sequencing of the double mutant did not reveal any point mutations in the RRDR region and it was understood that fitness revival along with low-level rifampicin resistance is not due to RRDR hot-spot mutation. Finally, to estimate the specific role of high intracellular c-di-AMP concentration driving positive epistatic interactions, we complemented  $\Delta pde$  category II  $cip^R$  mutant strain with a single copy integrating



vector pMV361-*pde*, which would bring down the c-di-AMP level to normalWT level. First, we checked the growth profile of the *M. smegmatis*  $\Delta pde$  (cip<sup>R</sup>) + pMV361-*pde* strain and found that the growth deficiency of the strain was visibly rectified (Fig. S3c) and upon repeating the double mutant selection assay in M9 minimal media, we found that the *M. smegmatis*  $\Delta pde$  (cip<sup>R</sup>) + pMV361-*pde* strain formed a significantly low number of rifampicin-resistant mutants, similar to *M. smegmatis*  $\Delta pde$  parental strain; whereas the *M. smegmatis*  $\Delta pde$  (cip<sup>R</sup>) + pMV361-Empty strain (vector control) still generated a high number of double (cip<sup>R</sup>, rif<sup>R</sup>) mutants (Fig. 3E). Hence, our data proved that a high intracellular c-di-AMP concentration coupled with a high fitness cost of drug mutation, potentially could drive the evolutionary pattern of the slow-growing strain; specifically, to revive the high fitness cost imposed by the first mutation, cells often spontaneously acquire secondary drug mutation and thus promoting multi-drug tolerance.


### c-di-AMP plays a role in persister cells regrowth by modulating resuscitation-promoting factor gene *rpfA* expression.

As our research already pointed out about the definite role of c-di-AMP in resistant mutant evolution, we also wanted to check if increased or lack of c-di-AMP concentration could play a role in the persister formation and outgrowth in *M. smegmatis*. In both laboratory and clinical scenarios, antibiotic treatment often gives a biphasic response with a rapid killing phase followed by a plateau which is typically represented by a 0.01–0.001% non-growing persister population<sup>39</sup>. These antibiotic-selected persister cells often pose a major threat to an effective antibiotic therapy because the persisters could resuscitate into normal growing cells at some point in time after the antibiotic treatment is terminated, resulting in recurrent infection<sup>40</sup>. First, we began our study by checking persister formation with ciprofloxacin (10X MIC) treatment and we could not find any significant difference (data not shown) between WT,  $\Delta disA$  and  $\Delta pde$  strains in terms of the minute percentage of the survived population after killing ~99.9% of the major population in the culture. Next, we checked the regrowth of persisters with the same strains in presence of a lower concentration of ciprofloxacin (3X MIC), which was extremely relevant in a clinical scenario when the optimum antibiotic concentration could not be maintained due to a variety of reasons. Our data suggested that the regrowth of cells in the complete absence (10X ciprofloxacin treatment followed by washing off the drug) and presence of a lower concentration of ciprofloxacin (3X ciprofloxacin treatment and no washing after 24 h) significantly decelerated by high c-di-AMP concentration in  $\Delta pde$  strain (Fig. 4A, Fig. S4a). The complementation strain *M. smegmatis*  $\Delta pde$  + pMV361-*pde* had a similar resuscitation profile to WT (Fig. 4A). To further evaluate the direct role of c-di-AMP in the resuscitation of persisters, we used a mutant strain of *M. smegmatis*  $\Delta pde$ , where the *disA* gene function was purposefully abolished by introducing a frameshift mutation in the ORF. As expected, this double mutant strain ( $\Delta pde$ , *disA*-out of frame) behaved like WT and further corroborated the previous observation that the high c-di-AMP concentration in  $\Delta pde$  strain is specifically responsible for slower resuscitation and it was not due to any polar effect (Fig. S4b). Next, we checked if the slower resuscitation of  $\Delta pde$  persister cells could result from more genetic mutants, we estimated the number of ciprofloxacin-resistant genetic mutants (cip<sup>R</sup>) by plating parallelly on ciprofloxacin containing plate. We found a visible increase in cip<sup>R</sup> mutants in the case of  $\Delta pde$  mutant strain which attained a remarkable ~93% mutant population takeover within 24 h of the killing, whereas in the case of WT strain it was ~52% of cells became ciprofloxacin mutants (Fig. 4B). To know more about the mechanistic insights, we dig into the  $\Delta pde$  strain's RNA-seq data generated by our group<sup>20</sup> and found that the *rpfA* (*MSMEG\_5700*) gene was significantly downregulated (transcriptionally) in the  $\Delta pde$  strain (log2 fold change – 3.0062). Previous studies suggested that the *rpfA* gene encodes for a secreted protein and participated in the resuscitation of non-growing cells<sup>41</sup>. A detailed search in a prokaryotic riboswitch database ([http://ribod.iiserkol.ac.in/genome\\_search2.php?id=NC\\_008596.1](http://ribod.iiserkol.ac.in/genome_search2.php?id=NC_008596.1)) revealed the presence of an *ydaO-yuaA* class of riboswitch just upstream of the *rpfA* gene. The *ydaO-yuaA* has been previously characterized as a c-di-AMP responsive riboswitch in *Bacillus subtilis* and other bacteria<sup>42</sup>. To check if there is any possible interaction between c-di-AMP and riboswitch element upstream of *rpfA*, we designed a transcriptional fusion by fusing 5'-UTR region of *rpfA* (434 bp) to promoter-less GFP in pMN406 plasmid. Next, we used this reporter plasmid in different strain backgrounds to check GFP fluorescence (as a measure of promoter induction) during the resuscitation phase of persisters. Indeed, we found a significantly slower induction of the  $P_{rpfA}$  in  $\Delta pde$  background when the minor population of antibiotic tolerant cells was allowed to regrow in fresh media after 15 h of ciprofloxacin treatment and washing off the drug. As a control, we used the double mutant strain ( $\Delta pde$ , *disA*-out of frame), where  $P_{rpfA}$  induction was considerably improved under identical conditions compared to  $\Delta pde$  strain (Fig. 4C). This important observation described the molecular basis of the high c-di-AMP driven slower resuscitation of persisters in *M. smegmatis*.

## Discussion

Bacterial second messengers have been shown to play important roles in the cellular physiology of different bacteria. In a previous study, we thoroughly studied the role of c-di-AMP in *M. smegmatis* starting from basic phenotypes modulation to stress response and antibiotic sensitivity<sup>20</sup>. As a continuation of that study, here we were particularly interested to explore the role of c-di-AMP in generating antibiotic tolerant cells. We used two different deletion mutants of *M. smegmatis* with varying c-di-AMP concentrations and confirmed that both spontaneous mutation frequency and mutation rate got increased by several folds when the intracellular c-di-AMP level is higher than usual. Exponentially grown  $\Delta pde$  strain did not show high mutation frequency against rifampicin possibly due to lack of DNA damage of the cells in that active phase of growth unless it is imposed externally (by ciprofloxacin treatment).

To confirm the direct involvement of high c-di-AMP, we included  $\Delta pde$  complementation (*M. smegmatis*  $\Delta pde$  + pMV361-*Pde*) and found that the hypermutation phenotype is reversed to the normal WT level. Though c-di-AMP has been previously shown to be involved in drug resistance of a particular class of antibiotics<sup>43,44</sup>,



**Figure 5.** Schematic representation of our proposed model showing how high c-di-AMP concentration in *M. smegmatis* drives error-prone DNA repair which results in a significant change in the mutational landscape and fitness of a cell and finally promotes multi-drug resistance. The figure was created using the paid license from BioRender ([www.biorender.com](http://www.biorender.com)).

this observation was novel in terms of showing how a second messenger directly contributes to the generation of genetic resistant mutants against different antibiotics with diverse mechanisms of action.

Next, we found that if cells were treated with a DNA-damaging agent (mutagen) such as UV irradiation, the possibility of genome-wide random mutations (*rpoB* gene selected in our case) is directly proportional to the increased c-di-AMP concentration; which is hypothesized to be linked with the lack or absence of the RecA mediated Homology directed repair (HDR) mechanism. This is in good agreement with the previous study<sup>15</sup> where it was shown that c-di-AMP directly interferes with the RecA enzyme activity in *M. smegmatis* with the disassembly of nucleoprotein complex. However, it was not known what could be the alternative pathway of DNA repair and the possible consequences of DNA damage in such conditions. Here we hypothesize that *M. smegmatis* cells tend to become largely dependent on the non-homologous end joining (NHEJ) pathway, which is fallible and can give rise to unwanted mutations. Our plasmid-based in vivo NHEJ assay result indeed pointed towards high mutation probability in  $\Delta pde$  strain as evidenced by a significant decrease in repair fidelity of the reporter gene *lacZ*. Conditional knockdown of the main component of the NHEJ pathway, Ku protein reverted the hypermutation phenotype in  $\Delta pde$  strain, which was helpful to precisely understanding the molecular basis of the phenotype. This section of our study was critically revealing the underlying mechanism of the observed hypermutation phenotype in a high c-di-AMP strain; more importantly showed, for the first time, according to our knowledge, how a bacterial second messenger can manifest a global shift in DNA damage repair function in a cell favoring the generation of spontaneous resistant mutants. Further, we did a mutant screening exercise of *cip<sup>R</sup>* mutants and discovered a predominantly high proportion of clones without QRDR mutations in  $\Delta pde$  strain, and often acquiring mutations in efflux pump repressor *lfrR*, which should be sufficient to grow at 10X MIC concentration of the drug. We hypothesize that the rarity of the QRDR mutations in high c-di-AMP strain is related to the high degree of error-prone NHEJ repair-driven loss of GyrA function. Occasionally,  $\Delta pde$  strain harbored a QRDR mutation (D94N) but that caused a considerable fitness loss of the strain and that could be also a reason for the non-selection of QRDR mutants. Fitness cost associated with antibiotic resistance has been studied in many cases<sup>45</sup>, particularly with fluoroquinolone resistance in different bacteria<sup>46,47</sup>, but our result interestingly demonstrated a significantly high liability of a *gyrA* mutation specifically in high c-di-AMP strain background, which triggered us to dig further and check if the hypermutant  $\Delta pde$  strain could rescue the fitness defect posed by a single point mutation in the QRDR region of the *gyrA* gene. It has been reported previously that the high fitness cost of an antibiotic resistance linked mutation sometimes gets compensated by a secondary mutation<sup>48,49</sup>. In the same line of observation, we found that while growing under stringent conditions for a long time where the fitness cost seemed to be very high, the high c-di-AMP strain tends to put a secondary mutation somewhere else in the genome to revive the fitness back. A further screening revealed that the *cip<sup>R</sup>* mutant

could evolve to become resistant to rifampicin (with significantly high resistant frequency compared to the  $\Delta pde$  parental strain) and thus neutralized the high fitness cost posed by the first mutation. In, WT and  $\Delta disA$  QRDR mutant strains (which also had a lesser growth deficiency), we could not observe such single mutant ( $cip^R$ ) to double mutant ( $cip^R$ ,  $rif^R$ ) transition and hence pointed out the relevant role of c-di-AMP in mediating positive epistatic interaction between two resistance genes. The fact that complementation of  $\Delta pde$  strain with single copy of  $pde$  gene (pMV361- $pde$ ) reversed the epistasis phenomenon pointed out the critical role of c-di-AMP in the process. There are few studies describing the link between epistasis with the emergence of multi-drug tolerance in mycobacteria<sup>50,51</sup> and our results indicated the possible role of c-di-AMP in this phenomenon.

In the final section of the study, we assessed how the c-di-AMP concentration plays a role in persister cells regrowth kinetics. The  $\Delta pde$  strain always grew slow during the regrowth phase following ciprofloxacin treatment and by multiple means when we neutralized the high c-di-AMP concentration in the  $\Delta pde$  strain, we observed uninhibited resuscitation similar to WT. This made us curious to discover if c-di-AMP was regulating some protein responsible for resuscitation, our RNA-seq data<sup>20</sup> and subsequent bioinformatic search indeed identified a particular gene  $rpfa$ , which seemed to be transcriptionally downregulated by c-di-AMP because of a putative riboswitch element in the 5'-UTR region. By using a GFP-based transcriptional fusion construct we indeed proved that  $P_{rpfa}$  had significantly reduced activity under high c-di-AMP concentration. The protein RpfA is known to function as a secreted growth factor that contributes to the resuscitation of dormant cells<sup>52,53</sup> and the fact that c-di-AMP regulates gene expression through riboswitch elements present in UTR of genes<sup>42,54,55</sup>, our study point out the unexplored important connection between the two and reveal the existence of such c-di-AMP responsive riboswitch in *M. smegmatis* with an associated phenotype.

All in all, our model suggested that c-di-AMP plays a key role in the resistant mutant generation and promotes multidrug tolerance in *M. smegmatis* (Fig. 5) as well as persists regrowth kinetics. In both cases, we have identified the underlying molecular mechanisms to elucidate the role of c-di-AMP and associated downstream components to drive antibiotic resistance. So far, as per our knowledge, there was no published report describing the direct involvement of a signaling messenger molecule to promote the generation of resistant mutants, especially promoting multi-drug tolerance via positive epistatic interaction between two different antibiotics, which we think is the major highlighting point of the study and extremely relevant for understanding the multi-drug tolerance phenotypes of mycobacteria in clinical perspective.

## Data availability

All data generated or analyzed during this study are included in the main manuscript and its supplementary information file. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Received: 24 May 2022; Accepted: 20 July 2022

Published online: 30 July 2022

## References

- Botsford, J. L. & Harman, J. G. Cyclic AMP in prokaryotes. *Microbiol. Rev.* **56**, 100 (1992).
- Haurlyuk, V., Atkinson, G. C., Murakami, K. S., Tenson, T. & Gerdes, K. Recent functional insights into the role of (p)ppGpp in bacterial physiology. *Nat. Rev. Microbiol.* **13**, 298–309 (2015).
- Römling, U., Galperin, M. Y. & Gomelsky, M. Cyclic di-GMP: The First 25 Years of a Universal Bacterial Second Messenger. *Microbiol. Mol. Biol. Rev.* **77**, 1 (2013).
- Commichau, F. M., Dickmanns, A., Gundlach, J., Ficner, R. & Stülke, J. A jack of all trades: The multiple roles of the unique essential second messenger cyclic di-AMP. *Mol. Microbiol.* **97**, 189–204 (2015).
- Cohen, D. *et al.* Cyclic GMP-AMP signalling protects bacteria against viral infection. *Nature* **574**, 691–695 (2019).
- Gomelsky, M. cAMP, c-di-GMP, c-di-AMP and now cGMP: Bacteria use them all! *Mol. Microbiol.* **79**, 562–565 (2011).
- Oppenheimer-Shaanan, Y., Wexselblatt, E., Katzhendler, J., Yavin, E. & Ben-Yehuda, S. c-di-AMP reports DNA integrity during sporulation in *Bacillus subtilis*. *EMBO Rep.* **12**, 594 (2011).
- Corrigan, R. M., Abbott, J. C., Burhenne, H., Kaever, V. & Gründling, A. c-di-AMP Is a new second messenger in *Staphylococcus aureus* with a role in controlling cell size and envelope stress. *PLoS Pathog.* **7**, e1002217 (2011).
- Luo, Y. & Helmann, J. D. Analysis of the role of *Bacillus subtilis*  $\sigma(M)$  in  $\beta$ -lactam resistance reveals an essential role for c-di-AMP in peptidoglycan homeostasis. *Mol. Microbiol.* **83**, 623–639 (2012).
- Corrigan, R. M. *et al.* Systematic identification of conserved bacterial c-di-AMP receptor proteins. *Proc. Natl. Acad. Sci. USA* **110**, 9084–9089 (2013).
- Kundra, S. *et al.* c-di-AMP is essential for the virulence of *Enterococcus faecalis*. *Infect. Immunity.* **89**, (2021).
- Woodward, J. J., Lavarone, A. T. & Portnoy, D. A. c-di-AMP secreted by intracellular *Listeria monocytogenes* activates a host type I interferon response. *Science* **328**, 1703–1705 (2010).
- Parvatiyar, K. *et al.* The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. *Nat. Immunol.* **13**, 1155–1161 (2012).
- Tang, Q. *et al.* Functional analysis of a c-di-AMP-specific phosphodiesterase MsPDE from *Mycobacterium smegmatis*. *Int. J. Biol. Sci.* **11**, 813–824 (2015).
- Manikandan, K. *et al.* The second messenger cyclic di-AMP negatively regulates the expression of *Mycobacterium smegmatis* *recA* and attenuates DNA strand exchange through binding to the C-terminal motif of mycobacterial RecA proteins. *Mol. Microbiol.* **109**, 600–614 (2018).
- Zhang, L., Li, W. & He, Z. G. DarR, a TetR-like transcriptional factor, is a cyclic Di-AMP-responsive repressor in *Mycobacterium smegmatis*. *J. Biol. Chem.* **288**, 3085–3096 (2013).
- Bai, Y. *et al.* *Mycobacterium tuberculosis* Rv3586 (DacA) is a diadenylate cyclase that converts ATP or ADP into c-di-AMP. *PLoS ONE* **7**, e35206 (2012).
- Manikandan, K. *et al.* Two-step synthesis and hydrolysis of cyclic di-AMP in *Mycobacterium tuberculosis*. *PLoS ONE* **9**, e86096 (2014).
- Yang, J. *et al.* Deletion of the cyclic di-AMP phosphodiesterase gene (*cnpB*) in *Mycobacterium tuberculosis* leads to reduced virulence in a mouse model of infection. *Mol. Microbiol.* **93**, 65–79 (2014).

20. Chaudhary, V., Pal, A., Singla, M. & Ghosh, A. Elucidating the role of c-di-AMP in *Mycobacterium smegmatis*: phenotypic characterization and functional analysis. *bioRxiv*. <https://doi.org/10.1101/2022.03.25.485789> (2022).
21. Kuthkoti, K., Kumar, P., Jain, R. & Varshney, U. Important role of the nucleotide excision repair pathway in *Mycobacterium smegmatis* in conferring protection against commonly encountered DNA-damaging agents. *Microbiology (Reading)* **154**, 2776–2785 (2008).
22. Swaminath, S., Pradhan, A., Nair, R. R. & Ajitkumar, P. The rifampicin-inactivating mono-ADP-ribosyl transferase of *Mycobacterium smegmatis* significantly influences reactive oxygen species levels in the actively growing cells. *bioRxiv*. <https://doi.org/10.1101/2020.01.10.902668> (2020).
23. David, H. L. Probability distribution of drug-resistant mutants in unselected populations of *Mycobacterium tuberculosis*. *Appl. Microbiol.* **20**, 810 (1970).
24. Luria, S. E. & Delbrück, M. Mutations of bacteria from virus sensitivity to virus resistance. *Genetics* **28**, 491–511 (1943).
25. Whiteford, D. C., Klingelhoets, J. J., Bambenek, M. H. & Dahl, J. L. Deletion of the histone-like protein (Hlp) from *Mycobacterium smegmatis* results in increased sensitivity to UV exposure, freezing and isoniazid. *Microbiology (Reading)* **157**, 327–335 (2011).
26. Gong, C. *et al.* Mechanism of nonhomologous end-joining in mycobacteria: A low-fidelity repair system driven by Ku, ligase D and ligase C. *Nat. Struct. Mol. Biol.* **12**, 304–312 (2005).
27. Palomino, J. C. *et al.* Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* **46**, 2720–2722 (2002).
28. Bose, M., Chander, A. & Das, R. H. A rapid and gentle method for the isolation of genomic DNA from mycobacteria. *Nucleic Acids Res.* **21**, 2529 (1993).
29. Li, X. Z., Zhang, L. & Nikaido, H. Efflux pump-mediated intrinsic drug resistance in *Mycobacterium smegmatis*. *Antimicrob. Agents Chemother.* **48**, 2415–2423 (2004).
30. Banerjee, S. K., Bhatt, K., Rana, S., Misra, P. & Chakraborti, P. K. Involvement of an efflux system in mediating high level of fluoroquinolone resistance in *Mycobacterium smegmatis*. *Biochem. Biophys. Res. Commun.* **226**, 362–368 (1996).
31. Gadagkar, R. & Gopinathan, K. P. Growth of *Mycobacterium smegmatis* in minimal and complete media. *J. Biosci.* **2**, 337–348 (1980).
32. Roy, S., Mir, M. A., Anand, S. P., Niederweis, M. & Ajitkumar, P. Identification and semi-quantitative analysis of *Mycobacterium tuberculosis* H37Rv *ftsZ* gene-specific promoter activity-containing regions. *Res. Microbiol.* **155**, 817–826 (2004).
33. Scholz, O., Thiel, A., Hillen, W. & Niederweis, M. Quantitative analysis of gene expression with an improved green fluorescent protein. *Eur. J. Biochem.* **267**, 1565–1570 (2000).
34. Zhang, L. & He, Z. G. Radiation-sensitive gene A (RadA) targets DisA, DNA integrity scanning protein A, to negatively affect cyclic Di-AMP synthesis activity in *Mycobacterium smegmatis*. *J. Biol. Chem.* **288**, 22426 (2013).
35. Bertrand, C., Thibessard, A., Bruand, C., Lecoq, F. & Leblond, P. Bacterial NHEJ: A never ending story. *Mol. Microbiol.* **111**, 1139–1151 (2019).
36. Aravind, L. & Koonin, E. V. Prokaryotic homologs of the eukaryotic DNA-end-binding protein Ku, novel domains in the Ku protein and prediction of a prokaryotic double-strand break repair system. *Genome Res.* **11**, 1365 (2001).
37. Paul, A., Nair, R. R., Jakkala, K., Pradhan, A. & Ajitkumar, P. Elevated levels of three reactive oxygen species and Fe(II) in the antibiotic-surviving population of mycobacteria facilitate de novo emergence of genetic resistors to antibiotics. *Antimicrob. Agents Chemother.* <https://doi.org/10.1128/AAC.02285-21> (2022).
38. Liu, J., Tariff, H. E. & Nikaido, H. Active efflux of fluoroquinolones in *Mycobacterium smegmatis* mediated by LfrA, a multidrug efflux pump. *J. Bacteriol.* **178**, 3791 (1996).
39. Helaine, S. & Kugelberg, E. Bacterial persisters: Formation, eradication, and experimental systems. *Trends Microbiol.* **22**, 417–424 (2014).
40. Fisher, R. A., Gollan, B. & Helaine, S. Persistent bacterial infections and persister cells. *Nat. Rev. Microbiol.* **15**, 453–464 (2017).
41. Kana, B. D. & Mizrahi, V. Resuscitation-promoting factors as lytic enzymes for bacterial growth and signaling. *FEMS Immunol. Med. Microbiol.* **58**, 39–50 (2010).
42. Nelson, J. W. *et al.* Riboswitches in eubacteria sense the second messenger c-di-AMP. *Nat. Chem. Biol.* **9**, 834 (2013).
43. Whiteley, A. T. *et al.* c-di-AMP modulates *Listeria monocytogenes* central metabolism to regulate growth, antibiotic resistance and osmoregulation. *Mol. Microbiol.* **104**, 212–233 (2017).
44. Pham, H. T. *et al.* Cyclic di-AMP oversight of counter-ion osmolyte pools impacts intrinsic cefuroxime resistance in *Lactococcus lactis*. *mBio* **12**, (2021).
45. Melnyk, A. H., Wong, A. & Kassen, R. The fitness costs of antibiotic resistance mutations. *Evol. Appl.* **8**, 273–283 (2015).
46. Johnning, A., Kristiansson, E., Fick, J., Weijdegård, B. & Larsson, D. G. J. Resistance mutations in *gyrA* and *parC* are common in *Escherichia* communities of both fluoroquinolone-polluted and uncontaminated aquatic environments. *Front. Microbiol.* **6**, 1355 (2015).
47. Agnello, M., Finkel, S. E. & Wong-Beringer, A. Fitness cost of fluoroquinolone resistance in clinical isolates of *Pseudomonas aeruginosa* differs by type III secretion genotype. *Front. Microbiol.* **7**, (2016).
48. Kunz, A. N. *et al.* Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations. *J. Infect. Dis.* **205**, 1821–1829 (2012).
49. Vincent, L. R. *et al.* In vivo-selected compensatory mutations restore the fitness cost of mosaic *penA* Alleles that confer ceftriaxone resistance in *Neisseria gonorrhoeae*. *mBio* **9**, (2018).
50. Borrell, S. *et al.* Epistasis between antibiotic resistance mutations drives the evolution of extensively drug-resistant tuberculosis. *Evol. Med. Public Health* **2013**, 65–74 (2013).
51. Sun, H. *et al.* Interaction between *rpsL* and *gyrA* mutations affects the fitness and dual resistance of *Mycobacterium tuberculosis* clinical isolates against streptomycin and fluoroquinolones. *Infect. Drug Resistance* **11**, 431–440 (2018).
52. Gupta, R. K. & Srivastava, R. Resuscitation promoting factors: A family of microbial proteins in survival and resuscitation of dormant mycobacteria. *Indian J. Microbiol.* **52**, 114 (2012).
53. Kana, B. D. *et al.* The resuscitation-promoting factors of *Mycobacterium tuberculosis* are required for virulence and resuscitation from dormancy but are collectively dispensable for growth in vitro. *Mol. Microbiol.* **67**, 672–684 (2008).
54. Wang, X. *et al.* A c-di-AMP riboswitch controlling *kdpFABC* operon transcription regulates the potassium transporter system in *Bacillus thuringiensis*. *Commun. Biol.* **2**, 1–10 (2019).
55. Gundlach, J. *et al.* Control of potassium homeostasis is an essential function of the second messenger cyclic di-AMP in *Bacillus subtilis*. *Sci. Signal* **10**, (2017).

## Acknowledgements

AG thanks the Ramalingaswami Re-entry Fellowship and the Department of Biotechnology (DBT), Government of India, for funding this work (BT/RLF/Re-entry/31/2017). AP acknowledges the Department of Biotechnology (DBT), Government of India for his fellowship. We thank Ms. Mamta Singla and Mr. Vikas Chaudhary for making plasmid constructs used in the study. We thank Prof. Dipankar Chatterji, MBU, IISc for valuable feedback on the work.



### Author contributions

A.G. conceptualized and designed of the study. A.P. and A.G. performed the experiments. A.P. and A.G. participated in data analysis and interpretation. A.P. and A.G. wrote the manuscript.

### Competing interests

The authors declare no competing interests.

### Additional information

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1038/s41598-022-17051-z>.

**Correspondence** and requests for materials should be addressed to A.G.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022, corrected publication 2022